BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Age-Related Macular Degeneration readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Age-Related Macular D
 egeneration\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04704921-5173@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT04704921)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3\, Age-Related Macular Degener
 ation.\nStudy: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gen
 e Therapy Administered Via Subretinal Delivery One Time in Participants Wi
 th nAMD\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04704921
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769048-5265@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:BI 1584862: Phase 2 readout est. (NCT06769048)
DESCRIPTION:BI 1584862\, phase 2\, Age-Related Macular Degeneration.\nStudy
 : A Study to Test Different Doses of BI 1584862 in People With a Distinct 
 Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy\n
 Estimated primary completion: 22 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bi-1584862#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06769048
URL:https://assetmemo.bio/drug/bi-1584862#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856577-11228@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT06856577)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneratio
 n\nEstimated primary completion: 22 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06856577
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495918-4967@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 6495918)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3\, Age-Related
  Macular Degeneration.\nStudy: Study to Evaluate the Efficacy and Safety o
 f Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age
 - Related Macular Degeneration\nEstimated primary completion: 8 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib-intravit
 real-implant-otx-tki#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06495918
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660667-5116@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:SAR402663: Phase 1/2 readout est. (NCT06660667)
DESCRIPTION:SAR402663\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovas
 cular Age-related Macular Degeneration\nEstimated primary completion: 18 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sar402663#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066606
 67
URL:https://assetmemo.bio/drug/sar402663#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904028-4978@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:faricimab: Phase 3 readout est. (NCT05904028)
DESCRIPTION:faricimab\, phase 3\, Age-Related Macular Degeneration.\nStudy:
  Home OCT-Guided Treatment Versus Treat and Extend for the Management of N
 eovascular AMD\nEstimated primary completion: 30 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/faricimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05904028
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510816-5301@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Vonaprument: Phase 3 readout est. (NCT06510816)
DESCRIPTION:Vonaprument\, phase 3\, Age-Related Macular Degeneration.\nStud
 y: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Inj
 ections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Rela
 ted Macular Degeneration (AMD) With Geographic Atrophy (GA)\nEstimated pri
 mary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/vonaprument#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06510816
URL:https://assetmemo.bio/drug/vonaprument#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215234-5224@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271013
DTEND;VALUE=DATE:20271014
SUMMARY:SAR446597: Phase 1/2 readout est. (NCT07215234)
DESCRIPTION:SAR446597\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR
 446597 in Participants With Geographic Atrophy Secondary to Age-related Ma
 cular Degeneration\nEstimated primary completion: 13 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sar446597#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07215234
URL:https://assetmemo.bio/drug/sar446597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482176-11228@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT07482176)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneratio
 n (AQUARIUS)\nEstimated primary completion: 15 November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07482176
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5167@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT06541704)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Age-Related Macular Degeneration
 .\nStudy: A Study Investigating Subcutaneously Administered Pozelimab in C
 ombination With Cemdisiran or Cemdisiran Alone in Adult Participants With 
 Geographic Atrophy\nEstimated primary completion: 31 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pozelimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5168@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT06541704)
DESCRIPTION:Cemdisiran\, phase 3\, Age-Related Macular Degeneration.\nStudy
 : A Study Investigating Subcutaneously Administered Pozelimab in Combinati
 on With Cemdisiran or Cemdisiran Alone in Adult Participants With Geograph
 ic Atrophy\nEstimated primary completion: 31 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461441-4978@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:faricimab: Phase 3 readout est. (NCT07461441)
DESCRIPTION:faricimab\, phase 3\, Age-Related Macular Degeneration.\nStudy:
  Efficacy and Durability of a Personalized Treat-and-extend Regimen of Far
 icimab for Treatment-naive Polypoidal Choroidal Vasculopathy\nEstimated pr
 imary completion: 30 November 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/faricimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07461441
URL:https://assetmemo.bio/drug/faricimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03999801-5173@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Surabgene lomparvovec: Phase 2 readout est. (NCT03999801)
DESCRIPTION:Surabgene lomparvovec\, phase 2\, Age-Related Macular Degenerat
 ion.\nStudy: Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03999801
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807969-5301@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vonaprument: Phase 3 readout est. (NCT07807969)
DESCRIPTION:Vonaprument\, phase 3\, Age-Related Macular Degeneration.\nStud
 y: An Open-label Extension Study of the Long-Term Safety of Vonaprument (A
 NX007) in Participants With Dry Age-Related Macular Degeneration (AMD) Wit
 h Geographic Atrophy (GA)\nEstimated primary completion: 31 July 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/vonaprument#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07807969
URL:https://assetmemo.bio/drug/vonaprument#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160179-5184@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:ABBV-6628: Phase 1/2 readout est. (NCT07160179)
DESCRIPTION:ABBV-6628\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves
  Through the Body of Adult Participants With Geographic Atrophy Secondary 
 to Age-Related Macular Degeneration\nEstimated primary completion: October
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-6628#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07160179
URL:https://assetmemo.bio/drug/abbv-6628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516132-4967@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 7516132)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3\, Age-Related
  Macular Degeneration.\nStudy: Study to Evaluate Long-Term Safety of Intra
 vitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Re
 lated Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-
 AMD-301 or OTX-TKI-2023-AMD-303 Study\nEstimated primary completion: 1 Aug
 ust 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib-in
 travitreal-implant-otx-tki#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07516132
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630649-11228@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Ixoberogene soroparvovec: Phase 2 readout est. (NCT07630649)
DESCRIPTION:Ixoberogene soroparvovec\, phase 2\, Wet Age-Related Macular De
 generation.\nStudy: Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosin
 g Study in Participants With Neovascular Age-related Macular Degeneration\
 nEstimated primary completion: June 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07630649
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007065-5173@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Surabgene lomparvovec: Phase 3 readout est. (NCT07007065)
DESCRIPTION:Surabgene lomparvovec\, phase 3\, Age-Related Macular Degenerat
 ion.\nStudy: Study to Assess the Injection Burden\, Adverse Events\, Chang
 e in Disease Activity\, and Long-Term Preservation of Visual Acuity of Sur
 abgene Lomparvovec in Adult Participants With Neovascular Age-Related Macu
 lar Degeneration (nAMD)\nEstimated primary completion: March 2033. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007065
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
